GSK plc
GLAXF · OTC
10/28/2025 | 9/30/2025 | 6/30/2025 | 3/31/2025 | |
|---|---|---|---|---|
| Market Cap | – | $62,567 | $55,251 | $62,464 |
| - Cash | – | $3,296 | $3,599 | $4,464 |
| + Debt | – | $17,750 | $0 | $18,432 |
| Enterprise Value | – | $77,021 | $51,652 | $76,432 |
| Revenue | $8,547 | – | $7,986 | $7,516 |
| % Growth | – | – | 6.3% | – |
| Gross Profit | $6,289 | – | $5,821 | $5,579 |
| % Margin | 73.6% | – | 72.9% | 74.2% |
| EBITDA | $3,361 | – | $3,230 | $3,093 |
| % Margin | 39.3% | – | 40.4% | 41.2% |
| Net Income | $2,013 | – | $1,443 | $1,624 |
| % Margin | 23.6% | – | 18.1% | 21.6% |
| EPS Diluted | 2.82 | – | 0.35 | 0.39 |
| % Growth | – | – | -10.3% | – |
| Operating Cash Flow | $3,028 | – | $2,096 | $1,145 |
| Capital Expenditures | -$428 | – | -$633 | -$448 |
| Free Cash Flow | $2,599 | – | $1,463 | $697 |